



NON-PAIN SYMPTOM MANAGEMENT

Ellen Fulp, PharmD, MSPC, BCGP
Director of Pharmacy Education, AvaCare, Inc.
April 6, 2021



OBJECTIVES

- Identify commonly reported non-pain symptoms experienced by palliative care patients
- Review non-pharmacologic and pharmacologic interventions for commonly experienced non-pain symptoms
- Discuss formulary medication selection



SYMPTOMS IN ADVANCED ILLNESS

- Fatigue
- Pain
- Gastrointestinal Symptoms
- Xerostomia
- Cachexia-Anorexia
- Insomnia
- Depression
- Dyspnea





DYSPNEA

- Breathing discomfort
 - Subjective
 - Sensations experienced or described may vary
- Symptoms: chest tightness, breathlessness, wheezing
- Underlying causes: tumor, COPD, CHF, pneumonia, fluid accumulation, anemia, aspiration, electrolyte imbalance, fatigue, anxiety
- Not always reflective of respiratory rate or oxygen saturation





- Non-pharmacologic Interventions
 - Calm patient
 - Semi-reclined or seated position
 - Modification of activity level
 - Cool compress to the cheek
 - Pursed-lip technique
 - Ensure air supply: open window, fan, oxygen



J Palliat Medicine 2011;14(10):1167-1172.





Opioids

- Systemic: Morphine is most widely studied
- Nebulized: Mixed data
- Benzodiazepines
 - Patient specific recommendation
 - Use caution when co-prescribing
- Others
 - Bronchodilators
 - Glucocorticoids
 - Underlying causes: COPD, SVC, tumor related upper airway obstruction
 - Diuretics
 - Loop diuretics for patients with congestive heart failure





SECRETIONS

- Turbulence as air moves over pooled secretions
 - produces noisy ventilation
- Education
- Non-Pharmacologic Interventions
 - Change position
 - Re-evaluate IV hydration




J Palliat Medicine 2013; 16(10): 1255-1259.



SECRETIONS

- Anticholinergics:
 - Atropine (Isopto Atropine®)
 - 1% Ophthalmic Solution sublingually at 1-2 drops hourly until controlled and then Q4-6H PRN.
 - Hyoscyamine (Levsin®)
 - 0.125-0.25mg SL Q6-8H PRN
 - Scopolamine (Transderm-Scop®)
 - 1.5mg transdermal patch placed behind the ear Q72H
 - Glycopyrrolate (Robinul®)
 - 1-2mg PO Q8H PRN







First, think drugs!

• Examples: Chemotherapy, opioids

Avoid triggers

• Examples: Strong smells, spicy foods

Small, frequent meals

• Examples: Bland foods, avoid greasy meals

Clear liquids, small sips



Medication	Dopamine Antagonist	Histamine Antagonist	Anti- Cholinergic	Serotonin Antagonist
Haloperidol	X***			
Prochlorperazine	X**	X*		
Promethazine	X*	X***	X**	
Metoclopramide	X**			X**
Ondansetron				X***
Chlorpromazine	X**	X**	X*	

*Low affinity to receptor, **Moderate affinity, ***High affinity



- Empiric therapy = Block dopamine
 - Metoclopramide 10mg PO q6h (may be dosed QID around meals/bedtime)
 - GI motility and dopamine antagonist
 - Available formulations: PO, IM, IV
 - Haloperidol 0.5mg PO q4-6h prn
 - Renal or hepatic impairment may require a dose reduction
 - Available formulations: PO, Subcutaneous, IV
 - Prochlorperazine 5-10mg PO q6-8h prn
 - Also blocks histamine receptor
 - Available formulations: PO, PR, IM, IV
- Alternatives: Promethazine, lorazepam, dexamethasone, ondansetron, chlorpromazine, octreotide



AGITATION

- Potential Causes
 - Physical discomfort
 - Environment
 - Urinary tract infection
 - Organ failure
 - Substance withdrawal
 - Psychosocial distress
 - Drugs:
 - Corticosteroids, anticholinergics, opioids, benzodiazepines, dopamine



J Palliat Med. 2013; 16(4):426-432.



AGITATION

- Non-pharmacologic Interventions
 - Reorient patient
 - Place
 - Date- calendar
 - Time-clock
 - Stable environment
 - Keep familiar objects in view
 - Calm, quiet
 - Caregiver continuity
 - Sleep hygiene
 - Eyeglasses and hearing aids
 - Rule out reversible causes
 - Monitor: bowel and bladder function



AGITATION

Antipsychotics

Haloperidol	 0.5mg PO Q4H PRN Formulations: PO, Subcutaneous, IV
Risperidone	 EPS at higher doses; mirrors first-generation drugs Formulations: PO (tablets, solution), ODT, long-acting IM injection
Quetiapine	Formulations: PO tablets (IR and XR)
Olanzapine	Formulations: PO tablets, ODT, IM injection (immediate and long-acting pamoate)
Ziprasidone	Formulations: PO capsules, IM injection (immediate-release)





Potential Causes

- Medication withdrawal
 - Benzodiazepines
 - Sedatives
 - Alcohol
- Illness exacerbation
- Social changes
- Uncontrolled symptoms
- Lack of knowledge or understanding
- Drugs: CNS stimulants, antipsychotics, beta-agonists, corticosteroids, nasal decongestants, thyroid replacements







- Non-pharmacologic Interventions
 - Regularly screen and assess
 - Support and reassurance
 - Use your interdisciplinary team!
 - Social workers, spiritual counsel, psychology
 - Cognitive Behavioral Therapy (CBT)
 - Relaxation, distraction, guided imagery
 - Treat the underlying cause








- Benzodiazepines
 - Lorazepam 0.5mg PO Q4H PRN
- Selective Serotonin Reuptake Inhibitors (SSRIs)
 - Citalopram 20mg PO daily
 - Sertraline 25-50mg PO daily
- Selective Norepinephrine Reuptake Inhibitors (SNRIs)
 - Duloxetine 30mg PO daily
- Antipsychotics or Anticonvulsants
 - Conventional or Atypical antipsychotics
 - Examples: Haloperidol or Quetiapine
 - Anticonvulsants
 - Example: Pregabalin



SEIZURES

- Screen for potential causes
 - Cancer with brain metastases, stroke, metabolic causes
 - Medications
 - Tricyclic antidepressants, bupropion, meperidine, tramadol
- Continue prophylactic medications for as long as possible
- If the potential for seizure is suspected, consider emergency seizure kit
 - Benzodiazepine in a non-oral formulation



SEIZURES


- Benzodiazepines are the drugs of choice (active seizure)
- First line therapies (rapid onset):
 - Lorazepam
 - 2mg PO/SL/IM/IV/PR Q15 Minutes PRN
 - Diazepam (Valium®)
 - 10mg PO/SL/IM/IV/PR Q15 Minutes PRN
 - Max dose = 40mg
 - Diazepam (Diastat®) Rectal Gel
 - 0.2mg/kg PR, round down to reduce ataxia and sedation
 - Second dose may be given 4-12 hours after initial dose
 - Should not be used more than once every 5 days

J Pain Symptom Manage. 2008 Jul;36(1):97-105.



PALLIATIVE SEDATION

- The use of sedative medications to relieve severe refractory symptoms at end of life
- Provides relief of intolerable suffering for terminally ill patients
- Refractory pain, dyspnea, agitated delirium and convulsions
 - Refractory = not adequately controlled by regimens that do not severely compromise consciousness





PALLIATIVE SEDATION

Medication	Starting Dose*	Tips			
Benzodiazepines					
Lorazepam	0.5mg PO Q4H PRN	Refrigerate solution			
Midazolam	0.5mg/hour infusion				
Antipsychotics					
Haloperidol	0.5mg PO Q4H PRN	Delirious patients			
Chlorpromazine	25mg PO Q4-12H PRN				
Barbiturates					
Phenobarbital	60mg PR Q4H PRN	Long half-life			
Pentobarbital	1mg/kg/hour infusion	Short-supply; costly!			
Opioids are NOT for palliative sedation!					







ADDITIONAL SYMPTOMS

CONSTIPATION


- Non-pharmacologic Interventions
- Formulary medications:
 - Bulk-forming laxatives
 - Enemas
 - Osmotic laxatives
 - Stimulant laxatives
 - Stool softeners
- Alternative medications:
 - Opioid Antagonists
 - Others (Linaclotide, Lubiprostone)





DIARRHEA

- Non-pharmacologic Interventions
 - BRAT diet, rehydration, dietary modifications
- Formulary medications:
 - Anti-motility agents
 - Anti-secretory/Absorbent agents
 - Bulk-forming agents
- Alternative medications
 - Antibiotics- C. difficile
 - Octreotide
 - Pancrelipase







- Non-pharmacologic interventions
 - Humidity, warm fluids, lozenges
- Treat underlying cause first
 - Example: intranasal glucocorticoids for post-nasal drip
- Formulary Medications
 - Opioids
 - Example: Morphine 5mg PO Q4H PRN
 - Centrally-acting non-opioid antitussives
 - Example: Dextromethorphan 10mg PO Q4-6H PRN
 - Non-opioid antitussives
 - Example: Benzonatate 100mg PO TID PRN



Oxford Textbook of Palliative Medicine. 5th Ed. Oxford: Oxford University Press; 2015



DYSPHAGIA

- Non-pharmacologic Interventions
- Oral route always preferred if patient can swallow
- Crush immediate-release medications for cost-savings
- Oral solutions or concentrates
 - Concentrated solutions may be administered SL or buccally
 - Volumes ≤ 1ml can be passively swallowed
- Rectal administration
 - Tablets
 - Suppositories



Oxford Textbook of Palliative Nursing. 5th Ed.
Oxford: Oxford University Press; 2015






- Non-pharmacologic Interventions
 - Breath holding, paper bags, ice application, inducing sneeze/cough
- Formulary Medications
 - Drugs that cause a reduction in gastric distention
 - Simethicone
 - Metoclopramide 10mg PO Q6H
 - Muscle relaxants
 - Baclofen 5mg PO Q6H
 - Dopamine antagonists
 - Haloperidol 2mg PO Q4H



INFECTIONS

- Not uncommon in end-of-life care
- Treating with antimicrobials at end-of-life is controversial
- Symptomatic improvement unlikely for all infections, especially when prognosis is weeks to short months
 - Treating urinary tract infections may provide symptomatic relief
 - Treating respiratory infections is less likely to provide symptomatic relief
- Weigh risks of adverse effects vs. benefit
- Consider treating symptoms of infection
 - Example: opioids for dyspnea



Fast Facts and Concepts #351



INSOMNIA

- Nonpharmacological Interventions
 - Good sleep hygiene!
- Medication selection is based on clinical symptoms, goals of care, and prognosis
 - Benzodiazepines
 - Zolpidem
 - Antidepressants
 - Melatonin



J Clin Sleep Med. 2017;13(2):307-349



PRURITUS

- Non-pharmacologic interventions
 - Treat dry skin, avoid chemicals, cool compress, cool environment, oatmeal bath
- Frequently used medications
 - Camphor and menthol
 - Topical steroids
 - Example: Hydrocortisone 1% cream applied topically BID PRN
 - Antifungals
 - Example: Clotrimazole 1% cream applied topically BID PRN
 - Antihistamines
 - Example: Diphenhydramine 25mg PO Q6H PRN
 - Other
 - Cholestyramine (liver induced) or Gabapentin (kidney induced)







QUESTIONS?

Ellen Fulp, PharmD, MSPC, BCGP AvaCare, Inc.

ellenf@avacare.biz

1-866-794-1044







THANK YOU!

REFERENCES

- Kamal AH, Maguire JM, Wheeler JL, Currow DC, Abernathy AP. Dyspnea Review for the Palliative Care Professional: Assessment, Burdens, and Etiologies. J Palliat Medicine 2011;14(10):1167-1172.
- Dudgeon, D, and Shadd J. Assessment and management of dyspnea in palliative care. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA.
- Campbell, Margaret L., and Hossein N. Yarandi. Death rattle is not associated with patient respiratory distress: is pharmacologic treatment indicated?. J Palliat Medicine 2013; 16(10): 1255-1259.
- Glare, P, Miller J, Nikolova T, Tickoo, R. Treating nausea and vomiting in palliative care: a review. Clin Interv Aging. 2011; 6:243-59.
- Irwin, et. al. Clarifying delirium management: Practical evidence-based expert recommendations for clinical practice. J Palliat Med. 2013; 16(4):426-432.
- Cherny, NI, Fallon, M, Kaasa, S, Portenoy, RK, Currow, D. Oxford Textbook of Palliative Medicine. 5th Ed. Oxford: Oxford University Press; 2015.



REFERENCES

- Droney J, Hall E. Status epilepticus in a hospice inpatient setting. J Pain Symptom Manage. 2008
 Jul;36(1):97-105.
- Cherny, N. Palliative Sedation. In: UpToDate, Smith, TJ(Section Ed), UpToDate, Waltham, MA.
- Wee B, Browning J, Adams A, et al.: Management of chronic cough in patients receiving palliative care: review of evidence and recommendations by a task group of the Association for Palliative Medicine of Great Britain and Ireland. *Palliat Med* 2012; 26: 780–7.
- Dahlin, CM and Cohen, AK. Chapter 11 Dysphagia, Xerostomia, and Hiccups. Oxford Textbook of Palliative Nursing. Ed. Betty Ferrell, Ed. Nessa Coyle, Ed. Judith Paice. New York: Oxford University Press, 2015. 210-213.
- Jablonski, L., Pruskowski, J. Antimicrobial therapy at the end of life. Fast Facts and Concepts #351. Palliative Care Network of Wisconsin. 2018.
- Sateia M.J., Buysse D.J., Krystal A.D., Neubauer D.N., Heald J.L. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017 Feb 15;13(2):307-349.
- Bruera, E, Dev R. Overview of managing common non-pain symptoms in palliative care. In: UpToDate, Post, TW, Smith TJ, Givens, J (Eds), UpToDate, Waltham, MA, 2021.

